Oncology

The National Comprehensive Cancer Network seeks to address issues related to treating HIV-positive patients with cancer, such as the potential for drug interactions.

The FDA previously approved abemaciclib for use in combination with fulvestrant in women with HR+/HER2- advanced breast cancer with disease progression following endocrine therapy.

Top news of the week from Specialty Pharmacy Times.

The FDA recently approved durvalumab (Imfinzi) for the treatment of patients with stage 3 non-small cell lung cancer (NSCLC) whose tumors are unresectable and whose disease has not progressed following treatment with chemoradiation.

Enzalutamide (Xtandi) demonstrates a significant reduction in metastasis or death from castration-resistant prostate cancer

Lorlatinib was designed to bypass non-small cell lung cancer mutations that promote drug resistance

Apalutamide (Erleada) was approved based on metastasis-free survival, which is a new clinical endpoint.

Smoking and alcohol consumption may exacerbate the risk of esophageal cancer associated with hot tea.

FDA expands the indication of abiraterone acetate (Zytiga) to include more patients with prostate cancer.

The risk of non-Hodgkin's lymphoma is elevated in patients with hepatitis C virus.

Immunotherapy combination beneficial for patients with lung cancer with a high tumor mutation burden.

Chronic HCV infection has been linked to low serum zinc and low metallothioneins expression in liver cells.

Ion channel inhibitors show promise reducing the high cost of conventional hepatitis C virus antiviral therapies.

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival (PFS) compared with chemotherapy in treatment-naïve patients with high tumor mutation burden (TMB) non–small cell lung cancer (NSCLC).

Newly-discovered gene mutations could double the risk of breast cancer.

A single blood test could diagnose 8 different types of cancer simultaneously.

Real-world evidence is becoming increasingly important for the development of treatment strategies in oncology.

Patients with a high risk of mortality may not choose first-line lung cancer treatment.

Fight or flight hormones could increase the production of tumor nerve cells.

Identifying current deficiencies in clinical practice can help pinpoint care practices that can be implemented for cancer survivors.

For many women, the fear of breast cancer is always present.

T-cells modified to express dominant-negative TGF-β receptor type 2 overcame cancer cell defenses.

An obesity drug may reduce the risk of metastatic prostate cancer.

Diabetes is the seventh-leading cause of death in the United States.

Gene expression may lead to castration-resistant prostate cancer.

Cancer registrars systematically capture all types of data about cancer and tumor diseases.

Patients with both hepatitis C and type 2 diabetes can develop fibrosis, steatosis, hepatocellular carcinoma, and resistance to antiviral treatment.

Court invalidates patent for abiraterone acetate (Zytiga).

Kohei Shitara, MD, Department of Gastrointestinal Oncology of National Cancer Center Hospital East, Japan, discusses the importance of the REVERCE clinical trial for specialty pharmacists.